Is Shionogi going global as a pharmaceutical company from Japan, or simply buying growth while its […]
Daiichi Sankyo is no longer best understood as a successful Japanese pharma company with a strong […]
Takeda’s savings programme is no longer an abstract investor slide. It has moved from corporate language […]